GlassScriptPhysician profile
Jordan Michael Burnham
NPI 1427312800
$6,331.25
in general payments reported to CMS, 2019-2025
24 companies · $926 in 2025
The $926 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.01 · 2020: $76.16 · 2021: $2,007 · 2022: $1,926 · 2023: $566 · 2024: $736 · 2025: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,227.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $3,297.01 | 2020-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $605.20 | 2020-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $368.03 | 2023-2025 | Syfovre |
| Genentech USA, INC. | $363.00 | 2021-2025 | Vabysmo |
| Abbvie INC. | $334.44 | 2022-2025 | Ozurdex |
| Astellas Pharma US INC | $277.09 | 2023-2025 | Izervay |
| Allergan, INC. | $194.30 | 2019-2021 | |
| Eyepoint US, INC. | $181.13 | 2021-2023 | |
| Bausch & Lomb Americas INC. | $125.71 | 2022-2024 | Xipere |
| Coherus Oncology, INC. | $92.33 | 2023-2024 | |
| Neurotech Pharmaceuticals, INC. | $90.33 | 2025 | |
| Astellas Pharma Global Development | $52.47 | 2024-2025 | Izervay |
| Sandoz INC. | $47.78 | 2024 | Cimerli |
| Novartis Pharmaceuticals Corporation | $47.65 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $46.71 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dutch Ophthalmic, USA | $36.96 | 2021 | |
| Dompe US, INC. | $27.35 | 2023 | Oxervate |
| Kala Pharmaceuticals, INC. | $26.23 | 2021 | |
| Mallinckrodt Hospital Products INC. | $24.86 | 2023 | Acthar |
| Iridex Corporation | $21.88 | 2021 | |
| Biotissue Holdings INC. | $20.00 | 2025 | |
| Harrow Eye, LLC | $19.96 | 2023 | Iheezo |
| Ani Pharmaceuticals, INC. | $19.84 | 2025 | Iluvien |
| Optos, INC. | $10.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Burnham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.